US-based Cleveland HeartLab (CHL) has acquired Mirisk cardiovascular disease risk assessment tool, developed at Stanford University School of Medicine.
As part of the deal, CHL acquired the intellectual property, copyrights and brand assets of Mirisk, which were previously owned by Aviir.
Cleveland HeartLab president and CEO Jake Orville said: "The Mirisk acquisition further illustrates CHL’s commitment to commercializing scientifically proven and medically relevant tests.
"CHL has a strong history of innovation and this acquisition further advances our mission of aiding clinicians in identifying risk and reducing cardiovascular events."
The tool has been developed to determine a patient’s potential long-term risk of a heart attack. It has been validated in an eight-year, 5,000 patient clinical trial.
Mirisk holds the capability to determine an individual’s probability of experiencing a heart attack within a five-year timeframe, and uses proprietary algorithm to analyze key blood proteins associated with the development of vulnerable plaque.